ArticleFrontiers in endocrinology2025
Allyl nonanoate as a novel bile-derived biomarker in metabolic dysfunction-associated steatotic liver disease.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We analyzed metabolites directly obtained from gallbladder bile, providing novel insights and identifying a potential antifibrotic target in metabolic dysfunction-associated steatotic liver disease (MASLD). Methods: We conducted metabolomic profiling of gallbladder bile samples collected during cholecystectomy from 68 individuals, including 19 healthy controls and 49 MASLD patients with varying degrees of hepatic fibrosis. We used mass spectrometry-based metabolomics to identify fibrosis-associated metabolites. Functional validation included Results: A total of 68 subjects were classified into healthy controls (n = 19), fibrosis stage 0-1 (n = 35), and fibrosis stage 2-3 (n = 14). Bile metabolomic profiling revealed distinct clustering among the groups, with eight metabolites showing a stepwise increase with fibrosis severity. Using the Human Metabolome Database, eight fibrosis-associated metabolites (M1-M8) were identified, among which M5 ( Conclusions: Bile metabolomic profiling in MASLD revealed distinct clustering patterns, with several fibrosis-associated metabolites demonstrating a stepwise increase with hepatic fibrosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.